Articles by Alan H. Bryce, MD
The panel highlights key ASCO GU 2025 data, including TALAPRO-2, PSMA PET, the PORTOS score, and emerging therapies like EZH2
The panel discusses data from PEACE-3 and maintaining ARSI therapy with emerging combination treatments.
The experts discuss treatment selection in mHSPC and share insights from STOPCAP and ARANOTE on ARSI use in older patients.
The panel covers metastasis-directed therapy and trials including SWOG 1802 in oligometastatic prostate cancer.
The panelists examine biomarker adoption challenges and the impact of PSMA PET on staging and treatment decisions.
Experts discuss advances in biomarker testing, treatment intensification, and the impact of TALAPRO-2 in prostate cancer care
Drs. Marshall, Bryce, and Castro discuss incorporating mCRPC PARP inhibitor toxicity and outcomes data into practice.
Drs. Marshall, Bryce, and Castro discuss PARP inhibitor monotherapy vs in combination with AR-targeting agents for mCRPC.
Alan H. Bryce, MD, highlights the positive TRITON3 data for rucaparib as a new standard of care for patients with mCRPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.